Advanced search
Publication Cover
Cancer Biology & Therapy Volume 14, 2013 - Issue 8
Submit an article Journal homepage
715
Views
4
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

Contradictory KRAS mutation test results in a patient with metastatic colon cancer

A clinical dilemma in the era of personalized medicine

Nicholas E Lamparella Department of Medicine; Division of Hematology/Oncology; Penn State Hershey Cancer Institute; Hershey, PA USACorrespondence[email protected] [email protected]
,
Bikramajit S Saroya Department of Medicine; Division of Hematology/Oncology; Penn State Hershey Cancer Institute; Hershey, PA USA
,
Zhaohai Yang Department of Pathology; Penn State Milton S. Hershey Medical Center; Hershey, PA USA
,
Nabeel E Sarwani Department of Radiology; Penn State Milton S. Hershey Medical Center; Hershey, PA USA
&
Wafik S El-Deiry Department of Medicine; Division of Hematology/Oncology; Penn State Hershey Cancer Institute; Hershey, PA USACorrespondence[email protected] [email protected]
Pages 699-702 | Received 08 May 2013, Accepted 19 May 2013, Published online: 12 Jun 2013

References

  • Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374 - 9; http://dx.doi.org/10.1200/JCO.2007.12.5906; PMID: 18202412
  • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626 - 34; http://dx.doi.org/10.1200/JCO.2007.14.7116; PMID: 18316791
  • Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931 - 7; http://dx.doi.org/10.1200/JCO.2009.22.4295; PMID: 19884549
  • Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295 - 308; http://dx.doi.org/10.1038/nrc2109; PMID: 17384584
  • Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311 - 9; http://dx.doi.org/10.1200/JCO.2007.13.1193; PMID: 18390971
  • Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040 - 8; http://dx.doi.org/10.1056/NEJMoa071834; PMID: 18003960
  • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658 - 64; http://dx.doi.org/10.1200/JCO.2006.08.1620; PMID: 17470858
  • Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091 - 6; http://dx.doi.org/10.1200/JCO.2009.21.9170; PMID: 19188670
  • Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, et al, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 2009; 7:778 - 831; PMID: 19755046
  • Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154:37 - 49; http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00006; PMID: 21200037
  • De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812 - 20; http://dx.doi.org/10.1001/jama.2010.1535; PMID: 20978259
  • Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883 - 92; http://dx.doi.org/10.1056/NEJMoa1113205; PMID: 22397650

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.